Trellus Health plc (AIM: TRLS) shares surged 125% in early trading after the company announced a six-month contract extension with Johnson & Johnson Health Care Systems for its Trellus Elevate platform, which supports patients living with inflammatory bowel disease.
The extension, which runs until mid-2026, will continue on the same economic terms, including a fixed monthly management fee. Trellus said the renewal was driven by strong engagement and satisfaction results achieved during the initial pilot phase, prompting J&J to expand patient access channels.
The company also highlighted ongoing deployment of its TrialSet™ solution, including work with ICON plc on a Takeda-sponsored trial and with PSI Inc. on Sanofi-sponsored studies.
For the year ended 2025, Trellus expects revenue of around $545,000 and said it has reduced its monthly cash burn to approximately $400,000. A £5 million convertible facility, recently approved by shareholders, is expected to extend the company’s cash runway into late Q1 2026, while discussions continue around additional funding.
Dr. Marla Dubinsky, CEO and Co-founder of Trellus Health plc said, “The extension of our collaboration with J&J represents further external validation of our platform and the engagement outcomes achieved during the pilot phase. Together with the rollout of TrialSet™ with leading CRO partners, Trellus Health operates across the full programme lifecycle, from clinical trials through commercial deployment, using our proprietary resilience methodology to support engagement and programme success. We are establishing a scalable go-to-market model for pharma, with continued focus on disciplined execution, recurring revenue growth and expansion across immunology and inflammation. We look forward to updating the market on further developments.“
